High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients

SIMPLE SUMMARY: Several available medications are involved in the treatment of metastatic castration-resistant prostate cancer (mCRPC). In this Taiwanese mCRPC cohort receiving enzalutamide patients with high tumor burden (HTB) were defined as those with either appendicular bony metastasis or viscer...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Yu-Ting, Chiang, Bing-Juin, Wu, Chia-Chang, Liao, Chun-Hou, Lin, Chia-Da, Chen, Chung-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392339/
https://www.ncbi.nlm.nih.gov/pubmed/34439119
http://dx.doi.org/10.3390/cancers13163966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392339/
https://www.ncbi.nlm.nih.gov/pubmed/34439119
http://dx.doi.org/10.3390/cancers13163966

Ejemplares similares